Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Convertible Debt (2023)

Historic Convertible Debt for Mereo BioPharma (MREO) over the last 1 years, with Q4 2023 value amounting to $4.4 million.

  • Mereo BioPharma's Convertible Debt changed N/A to $4.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $4.4 million, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Mereo BioPharma reported Convertible Debt of $4.4 million as of Q4 2023.
  • Mereo BioPharma's Convertible Debt's 5-year high stood at $4.4 million during Q4 2023, with a 5-year trough of $4.4 million in Q4 2023.